[Comparison of the cardiovascular predictive value of MDRD and CKD-EPI in estimating chronic kidney disease]. / Comparación del valor predictivo cardiovascular de MDRD y CKD-EPI en la estimación de la enfermedad renal crónica.

OBJECTIVE: To assess predictive value of the cardiovascular prognosis by comparing the two most used formulas for the estimation of glomerular filtration rate in hypertensive patients. MATERIAL AND METHODS: A retrospective cohort study was designed that included 405 patients diagnosed with essential hypertension. The patients were referred from Primary Care to the Hypertension and Vascular Risk Unit between January 1, 1998 and August 31, 1999. Blood pressure measurements, blood and urine analysis, and echocardiography were simultaneously performed. They were followed up for 12.5 years (mean [± IQR]: 10.61 [± 3.11] years) and 174 events were recorded. RESULTS: The study included 405 patients (53.8% women), with a mean age of 55.5 years. The estimated glomerular filtration rate according to the MDRD and CKD-EPI equations was 73.9±2.6 mL/min/1.73m(2) and 76.9±2.2 mL/min/1.73m(2), respectively. The prevalence of chronic kidney disease was 31.6% and 23.9%, respectively. Using the CKD-EPI equation led to the re-classification of 22.9% of patients. The incidence rate ratio (IRR [95%CI] for chronic kidney disease identified by the MDRD equation was 2.4 [1.8-3.3], and for the CKD-EPI calculation it was 2.5 [1.8 to 3.3]). CONCLUSIONS: Both equations estimate similar magnitudes of renal function, although the CKD-EPI equation has less false positives, and both have similar prognostic values in patients at high cardiovascular risk as well those at low risk.

[Carotid intima-media thickness distribution according to the stratification of cardiovascular risk by means of Framingham-REGICOR and score function charts]. / Distribución del grosor íntima-media carotídeo en función de la estratificación del riesgo cardiovascular según las funciones de Framingham-REGICOR y SCORE.

BACKGROUND: Carotid intima-media thickness (cIMT) has been suggested as a further tool for risk function charts. The aim of this study was to describethe relationship between cIMT and cardiovascular risk (CVR) estimation according to Framingham-REGICOR and SCORE equations. METHODS: Observational, cross-sectional cohort study from 362 hypertensive subjects. Demographic and clinical information were collected as well as laboratory, ultrasonographic and CVR estimation by the Framingham-REGICOR and SCORE functions. Statistical analysis was performed using SPSS software (version 20,0). To analyze the data, statistical tests such as Chi-square, T-test, ANOVA, and Pearson correlation coefficient were used. RESULTS: According to both functions, differences on mean cIMT were found between low CVR group and intermediate to high groups. No differences were found between intermediate and high risk groups (cIMT: 0,73mm low risk patients vs. 0,89 or 0,88mm respectively according to SCORE function and cIMT: 0,73 vs. 0,85 or 0,87mm respectively according to Framingham-REGICOR function). cIMT correlated positively with CVR estimation according to both SCORE (r=0,421; P<.01), and Framingham-REGICOR functions (r=0,363; P<.01). CONCLUSIONS: cIMT correlates positively with CVR estimated by SCORE and Framingham-REGICOR functions. cIMT in those subjects at intermediate risk is similar to those at high risk. Our findings highlight the importance of carotid ultrasound in identifying silent target-organ damage in those patients at intermediate CVR.

A comparison of indapamide SR 1.5 mg with both amlodipine 5 mg and hydrochlorothiazide 25 mg in elderly hypertensive patients: a randomized double-blind controlled study.

OBJECTIVE: To analyse the efficacy of indapamide sustained-release (SR) 1.5 mg in reducing blood pressure versus amlodipine 5 mg and hydrochlorothiazide 25 mg, in elderly hypertensive patients. DESIGN: Double-blind, randomized, 12 week study using three parallel groups. SETTING: European teaching hospitals and general practices. PATIENTS: Randomized patients, (n = 524) including 128 patients with isolated systolic hypertension (ISH); mean age: 72.4 years; mean systolic/diastolic blood pressures (SBP/DBP): 174.5/97.9 mmHg. MAIN OUTCOME MEASURES: Clinic systolic and diastolic blood pressure variations. RESULTS: Indapamide SR 1.5 mg demonstrates a similar efficacy to that of amlodipine 5 mg, as well as to that of hydrochlorothiazide 25 mg (equivalence P < 0.001); the mean decreases in SBP/DBP were -22.7/-11.8 mmHg, -22.2/-10.7 mmHg and -19.4/-10.8 mmHg, respectively. In the ISH subgroup, indapamide SR 1.5 mg tends to have greater efficacy than hydrochlorothiazide 25 mg in reducing the SBP (-24.7 versus -18.5 mmHg, respectively; equivalence P = 0.117), while similar results are obtained with amlodipine 5 mg (-23 mmHg, equivalence P < 0.001). The normalization rate was relatively high for indapamide SR 1.5 mg (75.3%), when compared with amlodipine (66.9%) and hydrochlorothiazide (67.3%), especially in the subgroup of isolated systolic hypertensive patients: 84.2 versus 80.0% for amlodipine, and versus 71.4% for hydrochlorothiazide. CONCLUSIONS: Indapamide SR 1.5 mg shows similar antihypertensive efficacy to amlodipine 5 mg and hydrochlorothiazide 25 mg in elderly hypertensive patients, while in patients with isolated systolic hypertension, indapamide SR 1.5 mg shows a similar efficacy to amlodipine 5 mg but a greater efficacy than hydrochlorothiazide 25 mg.

Effects on left ventricular mass and function of low doses of enalapril for systemic hypertension.

After 7 years of treatment with 20 mg of enalapril twice daily, regression of the initial left ventricular hypertrophy in a group of 24 patients with essential arterial hypertension was achieved: gradual reduction in the dosage to 10 or 5 mg twice daily caused no worsening of either blood pressure or ventricular structure or function.

[Effect of verapamil and nitrendipine on the left ventricular mass and function (systolic and diastolic) in arterial hypertension]. / Efecto de verapamilo y nitrendipino sobre la masa y función (sistólica y diasólica) ventricular izquierda en la hipertensión arterial.

BACKGROUND: To evaluate the effect of two calcium antagonists (verapamil and nitrendipine) on the regression of left ventricular mass and function (systolic and diastolic) by echocardiography-Doppler, in not treated hypertensive subjects. METHODS: 31 hypertensive subjects were studied in a randomized, placebo controlled, prospective and double blind trial. Verapamil (120-240 mg/day) was administered in 16 and nitrendipine (10-20 mg/day) in 15. The active drug therapy phase was 12 months with rest and effort tensional evaluation. Echo-Doppler was performed in the placebo phase, 6 and 12 months, evaluating left ventricular structure (septal and posterior-wall thicknesses, diameters and mass) and function (systolic and diastolic). RESULTS: Tensional control at rest and under effort was similar with both drugs, heart rate decreased only with verapamil. Left ventricular mass index decreased with verapamil and nitrendipine, due to reduction in the wall thicknesses (with verapamil from 158.5 +/- 31 to 135.7 +/- 20 g/m2 and with nitrendipine from 167.3 +/- 26 to 146.9 +/- 21 g/m2, p < 0.05). Left ventricular systolic function was not modified during the follow-up with both drugs. Only in the verapamil group some left ventricular diastolic function parameters improved (E from 0.82 +/- 0.11 to 0.95 +/- 0.14 and E/A/Age from 0.013 +/- 0.005 to 0.017 +/- 0.005; p < 0.05). CONCLUSIONS: Verapamil and nitrendipine exerts a similar tensional control at rest and under effort and left ventricular mass regression. The improvement of some diastolic function parameters in the verapamil group was probably due to bradycardia.

[Regression of left ventricular mass in arterial hypertension. Efficacy of 3 different treatment protocols]. / Regresión de la masa ventricular izquierda en la hipertensión arterial. Eficacia de tres diferentes pautas de tratamiento.

BACKGROUND: To evaluate the antihypertensive efficacy, at rest and under exercise, in patients treated with three different antihypertensive drugs and the modifications induced on the left ventricular mass. METHODS: Fifty hypertensive males, mean age 51 years, 15 received 50 mg/day of chlorthalidone, 20 atenolol (100 mg/day) and 15 enalapril (20-40 mg/day). Baseline pressure control and echocardiogram, and 3, 6 and 9 months after starting therapy were performed. Thickness of the interventricular septum and posterior left ventricular wall in mm, left ventricular mass index in g/m2 were determined. RESULTS: The baseline septum in the diuretic group was 15 +/- 3 mm and 14 +/- 3 mm at 9 months, in the atenolol group was 16 +/- 3 mm and 12 +/- 2 mm (p less than 0.001), and in the enalapril group 15 +/- 2 mm and 12 +/- 3 mm (p less than 0.01). The posterior wall was 14 +/- 3 mm and 13 +/- 2 mm in the diuretic group, in the atenolol group 15 +/- 2 mm and 12 +/- 2 mm (p less than 0.001) and in the enalapril group 15 +/- 2 mm and 12 +/- 3 mm (p less than 0.01). The left ventricular mass index was in he diuretic group 153 +/- 45 g/m2 and 146 +/- 36 g/m2, in the atenolol group 167 +/- 34 g/m2 and 128 +/- 24 g/m2 (p less than 0.001) and in the enalapril group 156 +/- 36 g/m2 and 131 +/- 26 g/m2 (p less than 0.05). CONCLUSIONS: The antihypertensive efficacy at rest was similar with the three drugs, being under exercise superior atenolol and enalapril. Only atenolol and enalapril induced regression of left ventricular mass.

[The midterm inefficacy of 2 different dosages of chlorthalidone (50 and 25 mg/day) in the regression of left ventricular mass in arterial hypertension]. / Ineficacia a medio plazo de dos diferentes dosificaciones de clortalidona (50 y 25 mg/día) en la regresión de la masa ventricular izquierda en la hipertensión arterial.

BACKGROUND: To evaluate the antihypertensive efficacy at rest and under exercise, and the modifications induced on the left ventricular mass in patients treated with two different doses of a diuretic. METHODS: Fifty hypertensive males, mean age 51 years, received during nine months 50 mg/day of chlortalidone and thirteen 25 mg/day for the next nine months. Baseline tension control and echocardiogram and each three months after starting therapy during the two phases of the study were performed. Thickness of the interventricular septum and posterior left ventricular wall in mm, left ventricular mass index in g/m2 were determined. RESULTS: The baseline septum was 15 +/- 3.3 mm, 14.6 +/- 3.1 mm at 9 months and 14.5 +/- 2.9 mm at 18 months, the posterior wall was 14.1 +/- 3.1 mm at baseline, 13.7 +/- 2.9 mm at 9 months and 13.6 +/- 2.9 mm at 18 months. The left ventricular mass index was 153 +/- 45 g/m2 at baseline, 146 +/- 36 g/m2 at 9 months and 144 +/- 39 g/m2 at 18 months. The antihypertensive efficacy at rest and under exertion was similar for the two doses of chlortalidone. CONCLUSIONS: After nine months of therapy the two doses of chlortalidone (50 and 25 mg/day) failed in reducing left ventricular mass. However, the design of the study and the small number of subjects enrolled introduce several important limitations to both the interpretation of our results and conclusions.

[Captopril in single dose in the treatment of essential arterial hypertension]. / Captopril en dosis única en el tratamiento de la hipertension arterial esencial.

Seventy one mild to moderate essential hypertensive patients receiving out-patient treatment with Captopril--inhibitor of the conversion enzyme--during a period of six months, are studied. The therapeutic goal (DAP less than 95 mm Hg.) was reached in 88% of the cases, with just a single Captopril dose of 50 mg/day in 42 patients (59.1%). AP decreased from 174.2/100.2 mm Hg. to 149.2/84.0 mm Hg. (p less than 0.001). Any significant changes in heart rate nor in body weight were observed. Side effects were rare (just in two patients), although their intensity determined in both cases the interruption of treatment. Finally, and improvement in the metabolic profile of patients was observed, with reduction in glucose, cholesterol, triglycerides and uric acid at the end of the study.

[The efficacy of nicardipine in treating arterial hypertension in elderly patients. A multicenter outpatient study]. / Eficacia de la nicardipina en el tratamiento de la hipertensión arterial en pacientes ancianos. Estudio multicéntrico en régimen de ambulatorio.

In this open study, 210 patients from both sexes, age above 60 years and diagnosis of AHT, were included. All patients were treated, following the washing-out phase, with a calcium antagonist dihydropyridine: nicardipine, at a doses of 60 mg/day for 12 weeks. A significant reduction in SAP (from 168.97 to 152.25 mm Hg.) and DAP (from 98.17 to 87.63 mm Hg.) was observed, without modifications in the cardiac rate. In addition, a low incidence of adverse effects and a high biological tolerance of the drug has been demonstrated during the whole study.

[Nitrendipine in the treatment of mild-moderate essential arterial hypertension. Ambulatory study in Primary Care]. / Nitrendipino en el tratamiento de la hipertensión arterial esencial ligera-moderada. Estudio ambulatorio en Atención Primaria.

A non-comparative open clinical pharmacological surveillance study was conducted, in which 427 patients from both sexes with diagnosis of light to moderate essential arterial hypertension were included. All patients were treated with nitrenpine, a dihydropyridinic calcium antagonist during a 28-week period. The initial dosage was 10 mg/day, increasing such dosage to 20 and 40 mg/day and associating it with a thiazidic diuretic in those patients showing no antihypertensive response (diastolic arterial pressure (DAP) of 90 mmHg or a reduction of 10 mmHg in baseline figures). A significant decrease was observed in systolic arterial pressure (from 159.3 +/- 12.6 to 149.2 +/- 12.2 mmHg) and in Dap (from 94.8 +/- 9.6 to 86.7 +/- 10.5 mmHg), p < 0.001, with effectivity in 66.3% of patients (65% receiving monotherapy; 10.3% combined therapy: nitrendipine and diuretic). No modifications were observed in heart rate nor in the biological-metabolic parameters under study. Side effects had a low incidence (15.9% of patients, with a 4.7% of drop-outs) and were well-tolerated in most cases. Given these results, we can conclude that nitrendipine is an effective and safe drug for the treatment of light to moderate arterial hypertension.

[Cerebrovascular disease and associated risk factors]. / Enfermedad cerebrovascular y factores de riesgo asociados.

In this report we are analysing the clinical history of 193 patients who were admitted to our medical department due to stroke during a period of two years. The patients were divided into two groups depending on wether they had ischemic or hemorrhagic pathology, analysing the presence of vascular risk factors in both groups. From the obtained results we have to point out, in both groups of patients, hypertension together with mellitus diabetes, giving clear proof of this, being the most frequent association of risk factors. We also have to point out the low percentage of patients with a lack of all the analysed risk factors, being also, that the average age was notably superior than the global.

[Renal oncocytoma and arterial hypertension. Report of a case]. / Oncocitoma renal e hipertensión arterial. A propósito de un caso.

We present the case of a patient with refractory arterial hypertension, during the study of which a renal mass was discovered and diagnosed after the surgical intervention of an oncocytoma. We review the clinical, diagnostic and therapeutic characteristics of this entity. In addition, the lack of a clear association between renal oncocytoma and arterial hypertension is stressed.

Left ventricular systolic function after marked reduction of ventricular hypertrophy induced by 5 years' enalapril treatment.

OBJECTIVES: To determine the effects of long-term treatment of essential hypertension with an angiotensin-converting enzyme inhibitor as regards arterial pressure at rest and during exercise, left ventricular mass and functional sequelae. PATIENTS AND METHODS: Twenty-six patients with previously untreated essential hypertension took enalapril 20 mg twice daily for 5 years. Cardiovascular parameters were determined by two-dimensionally guided M-mode echocardiography in a pre-treatment placebo phase, 8 weeks and 1, 3 and 5 years after the start of therapy, and 8 weeks after drugs were discontinued. RESULTS: Therapy reduced resting arterial pressure from 156/105 to 128/84 mmHg (P < 0.001) and arterial pressure during exercise from 205/113 to 172/94 mmHg (P < 0.0011). After 1, 3 and 5 years' therapy, left ventricular mass index had decreased by 15, 28 and 39% respectively (P < 0.001 in each case). Eight weeks after treatment was halted, arterial pressure at rest and during exercise had returned to pre-treatment values, but decreased left ventricular mass was maintained. Left ventricular pump function had improved after 5 years' treatment, and this improvement was maintained during the 8 weeks without treatment. CONCLUSIONS: Significant reductions in arterial pressure at rest and during exercise were achieved by 8 weeks' treatment with enalapril and maintained during 5 years' further treatment, while a marked reduction in left ventricular mass took place progressively throughout the 5 year period. Reduction of myocardial hypertrophy by enalapril appeared to be beneficial rather than detrimental to cardiac pump performance.